Join
Live feed
·
PRReleasevia Quantisnow
Cadrenal Therapeutics Inc. logo

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress

ByQuantisnow·Wall Street's wire, on your screen.
CVKD· Cadrenal Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CVKD (Cadrenal Therapeutics Inc.) and more on Quantisnow.